Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.

Inclusion Criteria:

- Patients which participated in double blind study

Exclusion Criteria:

• Patients with intolerable toxicity.
• Patients which confirmed progressive disease during double blind study.
• Patients which have received concurrent anti-cancer therapy during double blind study.